Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma

被引：0

作者：

Wen, P. Y. ^{[1
]}

Shih, K. ^{[2
]}

Schiff, D. ^{[3
]}

Brachmann, R. ^{[4
]}

Weitzman, R. ^{[4
]}

Cloughesy, T. ^{[5
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[2] Sarah Cannon Res Insititute, Neurooncol, Nashville, TN USA

[3] Univ Virginia Hlth Syst, Neurol, Charlottesville, VA USA

[4] BeiGene USA Inc, Clin Dev, Emeryville, CA USA

[5] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

421TiP

引用

页数：1

共 50 条

[31] Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer
Evans, Elizabeth E.
Fisher, Terrence Lee
Mallow, Crystal L.
Foster, Amber
Leonard, John E.
Chaney, Marya F.
Mekhail, Tarek
Seetharamu, Nagashree
Steuer, Conor Ernst
Saba, Nabil F.
Adkins, Douglas
Beck, J. Thaddeus
Algazi, Alain Patrick
Burtness, Barbara
Baumgart, Megan
Giampoli, Ellen
Hager, Steven Jeffrey
Chay, Christopher H.
Spira, Alexander I.
Zauderer, Maurice
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32] Safety and Effect of Radiation Therapy Combined with Anti-PD-1 Antibody SHR-1210 as First-Line Treatment on Patients with Intolerable Concurrent Chemoradiotherapy Esophageal Cancer: A Phase 1B Clinical Trial
Pang, Q.
Li, X.
Zhang, W.
Qian, D.
Zhang, B.
Chen, X.
Chen, X.
Wang, J.
Zhao, L.
Yuan, Z.
Wang, P.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E39 - E39
[33] A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)
Dai, Guang-Hai
Jia, Ru
Si, Haiyan
Wang, Zhi-Kuan
Deng, Guo-Chao
Zhang, Nan
Liu, Fang-Fang
Shi, Yue
Zhang, Yao-Yue
Jia, Yu-Shan
Zhang, Bei
Tong, Shuang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
van de Donk, Niels W. C. J.
Popat, Rakesh
Zonder, Jeffrey A.
Minnema, Monique C.
Larsen, Jeremy
Tuong Vi Nguyen
Chen, Min S.
Bensmaine, Amine
Cota, Mariana
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Han, Hyo
Diab, Sami
Alemany, Carlos
Basho, Reva
Brown-Glaberman, Ursa
Meisel, Jane
Pluard, Timothy
Cortes, Javier
Dillon, Patrick
Ettl, Johannes
Kuemmel, Sherko
Sanchez, Luis Manso
Oliveira, Mafalda
O'Shaughnessy, Joyce
Papish, Steven
Sinha, Rajni
Sterrenberg, Danielle
Stringer-Reasor, Erica
Tsai, Michaela
Vazquez, Rafael Villanueva
Wuerstlein, Rachel
Wang, Yinghui
Wang, Zejing
Boni, Valentina
CANCER RESEARCH, 2020, 80 (04)
[36] CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
Verschaeve, V.
D'Hondt, L. A.
Verbeke, L. M. J.
Van Fraeyenhove, F.
Du Four, S.
Duerinck, J.
Neyns, B.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[37] PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218)
Kizilbash, Sani
Piccioni, David
Sahebjam, Solmaz
Villano, John
Jaeckle, Kurt
Welch, Mary
Kong, Xiao-Tang
Holdhoff, Matthias
Lammers, Anita
Remick, Adam
Reid, Joel
Allred, Jacob
Port, John
Lanza, Ian
McBrayer, Samuel
Kunos, Charles
Shapiro, Geoffrey
Adjei, Alex
NEURO-ONCOLOGY, 2022, 24 : 75 - 75
[38] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Meisel, Jane Lowe
Pluard, Timothy J.
Vinayak, Shaveta
Stringer-Reasor, Erica Michelle
Brown-Glaberman, Ursa
Dillon, Patrick Michael
Basho, Reva K.
Varadarajan, Ramya
O'Shaughnessy, Joyce
Han, Hyo S.
Sinha, Rajni
Fox, Jenny R.
Villanueva, Rafael
Chen, Lin Chi
Wu, Sheng
Li, Hong
Tran, Sinhan
Manso, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Dillon, Patrick
Basho, Reva
Han, Hyo S.
Kolberg, Hans-Christian
Tkaczuk, Katherine
Zahrah, George
Gion, Maria
Voss, Herman
Meisel, Jane
Pluard, Timothy
Fox, Jenny
Oliveira, Mafalda
Brown-Glaberman, Ursa
Stringer-Reasor, Erica
Manso, Luis
Kuemmel, Sherko
Chen, Lin Chi
Wu, Sheng
Croft, Brandon
Boni, Valentina
CANCER RESEARCH, 2023, 83 (05)
[40] Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).
Lim, Kian-Huat
Spencer, Kristen Renee
Safyan, Rachael A.
Picozzi, Vincent J.
Varghese, Anna M.
Siolas, Despina
Perez, Kimberly
Clift, Sheena
Denis, Louis J.
Bhambhani, Vijeta
Hill, Stacey
Pachter, Jonathan A.
Pultar, Philippe
Hidalgo, Manuel
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →